A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007 (RAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01061788
Recruitment Status : Active, not recruiting
First Posted : February 3, 2010
Last Update Posted : February 12, 2018
NantCell, Inc.
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Jeffrey Clarke, Duke University Medical Center

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : June 2018
  Estimated Study Completion Date : June 2019